INT96814

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 2001
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 13
Total Number 13
Disease Relevance 10.64
Pain Relevance 1.61

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (APOE) aging (APOE) Golgi apparatus (APOE)
lipid metabolic process (APOE) cytoplasm (APOE) lipid binding (APOE)
Anatomy Link Frequency
adipose tissue 1
astrocytes 1
intestine 1
APOE (Homo sapiens)
Pain Link Frequency Relevance Heat
Bioavailability 2 100.00 Very High Very High Very High
Multiple sclerosis 13 99.84 Very High Very High Very High
tetrodotoxin 2 99.84 Very High Very High Very High
Action potential 2 99.48 Very High Very High Very High
chemokine 20 98.64 Very High Very High Very High
Calcium channel 4 98.40 Very High Very High Very High
Inflammation 245 97.76 Very High Very High Very High
antagonist 18 76.80 Quite High
Inflammatory response 45 64.48 Quite High
ischemia 16 62.12 Quite High
Disease Link Frequency Relevance Heat
Disorder Of Lipid Metabolism 48 100.00 Very High Very High Very High
Demyelinating Disease 19 99.84 Very High Very High Very High
Disease 174 99.60 Very High Very High Very High
Atherosclerosis 63 99.30 Very High Very High Very High
Neuromyelitis Optica 162 99.28 Very High Very High Very High
Obesity 95 98.16 Very High Very High Very High
INFLAMMATION 319 97.76 Very High Very High Very High
Adhesions 14 97.76 Very High Very High Very High
Stress 34 96.64 Very High Very High Very High
Alzheimer's Dementia 4 96.32 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In the presence of beta A4-peptide fragments, astrocytes stop their synthesis of ApoE resulting in a massive reduction in the bioavailability of ApoE.
Negative_regulation (reduction) of ApoE in astrocytes associated with bioavailability
1) Confidence 0.59 Published 2001 Journal Biochem. Soc. Symp. Section Abstract Doc Link 11447828 Disease Relevance 0.33 Pain Relevance 0.21
This could lead to a reduced apoE protective effect, during the development of adipose tissue [7] and, in particular, during inflammation, thus potentially leading to an increased risk of developing atherosclerosis.
Negative_regulation (reduced) of apoE in adipose tissue associated with inflammation, atherosclerosis and obesity
2) Confidence 0.56 Published 2010 Journal Lipids Health Dis Section Body Doc Link PMC2917427 Disease Relevance 1.07 Pain Relevance 0.12
The ApoE effects on calcium are not affected by the blockade of action potentials with tetrodotoxin, or by inhibition of common ApoE binding sites.
Negative_regulation (inhibition) of ApoE associated with tetrodotoxin and action potential
3) Confidence 0.43 Published 2001 Journal Biochem. Soc. Symp. Section Abstract Doc Link 11447828 Disease Relevance 0.39 Pain Relevance 0.23
Furthermore, an NCoA6 isoform lacking the inhibitory C-terminal STL region, but which retains LxxLL-1 and AD2, might be expected to be a more active isoform of NCoA6.
Negative_regulation (retains) of AD2
4) Confidence 0.41 Published 2008 Journal Nuclear Receptor Signaling Section Body Doc Link PMC2254332 Disease Relevance 0 Pain Relevance 0
When a region of NCoA6(NRC) containing LxxLL-AD2 was expressed in mammalian cells, it was found to be only moderately active when expressed alone.
Negative_regulation (region) of AD2
5) Confidence 0.41 Published 2008 Journal Nuclear Receptor Signaling Section Body Doc Link PMC2254332 Disease Relevance 0 Pain Relevance 0
ApoE is reported to have neurotrophic activity, and CSF ApoE levels are reduced in MS, a disease analogous to NMO [44].
Negative_regulation (reduced) of ApoE associated with neuromyelitis optica, multiple sclerosis and disease
6) Confidence 0.33 Published 2009 Journal Molecular Vision Section Body Doc Link PMC2730746 Disease Relevance 1.44 Pain Relevance 0.13
Therefore, reduced levels of ApoE may contribute to the progression of NMO.


Negative_regulation (reduced) of ApoE associated with neuromyelitis optica
7) Confidence 0.25 Published 2009 Journal Molecular Vision Section Body Doc Link PMC2730746 Disease Relevance 1.43 Pain Relevance 0.15
-driven molecules in atherosclerosis is provided by mice with combined deficiencies of apolipoprotein E (apoE) and the IFN-?
Negative_regulation (deficiencies) of apoE associated with atherosclerosis and disorder of lipid metabolism
8) Confidence 0.24 Published 2005 Journal Immun Ageing Section Body Doc Link PMC1166571 Disease Relevance 1.52 Pain Relevance 0.20
-driven molecules in atherosclerosis is provided by mice with combined deficiencies of apolipoprotein E (apoE) and the IFN-?
Negative_regulation (deficiencies) of apolipoprotein E associated with atherosclerosis and disorder of lipid metabolism
9) Confidence 0.24 Published 2005 Journal Immun Ageing Section Body Doc Link PMC1166571 Disease Relevance 1.52 Pain Relevance 0.20
We examined the relation between specific single nucleotide polymorphisms (SNPs), including those in the RAS, apolipoprotein E and alpha-adducin, and renal function decline assessed by estimated glomerular filtration rate (eGFR) over an 11-year period in 2578 Caucasian participants of the Nurses' Health Study.
Negative_regulation (decline) of apolipoprotein E associated with disorder of lipid metabolism
10) Confidence 0.20 Published 2009 Journal PLoS ONE Section Abstract Doc Link PMC2650781 Disease Relevance 0.28 Pain Relevance 0
More investigation into this effect would be warranted prior to making any definitive conclusions regarding the effectiveness of apoE.
Negative_regulation (effectiveness) of apoE
11) Confidence 0.14 Published 2006 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC1510947 Disease Relevance 0.94 Pain Relevance 0.12
Mice that were double deficient in apolipoprotein E and apolipoprotein ?
Negative_regulation (deficient) of apolipoprotein E associated with disorder of lipid metabolism
12) Confidence 0.03 Published 2001 Journal Curr Control Trials Cardiovasc Med Section Body Doc Link PMC64829 Disease Relevance 0.64 Pain Relevance 0.03
Specific blockade of LPG and LPPG by monoclonal antibody EH5 reduces intestinal inflammation and tissue damage in a severe combined immunodeficient (SCID) mouse model of intestinal amebiasis with human intestine xenograft [120].
Negative_regulation (blockade) of LPG in intestine associated with amebic dysentery, inflammation and severe combined immunodeficiency
13) Confidence 0.01 Published 2010 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC2817369 Disease Relevance 1.08 Pain Relevance 0.22

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox